mRNA-1653 Vaccine Description
mRNA-1653 is a combination vaccine that consists of two distinct mRNA sequences encoding the fusion (F) proteins of hMPV and PIV3 formulated in Moderna’s proprietary lipid nanoparticle (LNP) technology.
mRNA-1653 Vaccine Indication
mRNA-1653 is designed to protect against human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3), two viruses that cause respiratory infections.
mRNA-1653 Vaccine News
November 4, 2021 - Moderna is enrolling seropositive pediatric participants (12-36 months of age) in the Phase 1 study of the hMPV/PIV3 study (mRNA-1653). The first cohort in this study is fully enrolled.
September 17, 2020 - Moderna reported the First 10 pediatric patients dosed in Phase 1 study of hMPV/PIV3 vaccine (mRNA-1653). Sites have re-opened and are actively recruiting participants. Moderna owns worldwide commercial rights to mRNA-1653.
mRNA-1653 Vaccine Clinical Trials
Moderna has begun to recruit for Phase 1 Clinical Trial NCT04144348.
Clinical Trial NCT03392389: Phase 1 Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults. This study was completed on July 29, 2019. No results have been posted.